Caricamento...

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited. How to better treat patients with unmethylated MGMT is unknown. We performed a trial combining erlotinib and bevacizuma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Neurooncol
Autori principali: Raizer, J. J., Giglio, P., Hu, J., Groves, M., Merrell, R., Conrad, C., Phuphanich, S., Puduvalli, V. K., Loghin, M., Paleologos, N., Yuan, Y., Liu, D., Rademaker, A., Yung, W. K., Vaillant, B., Rudnick, J., Chamberlain, M., Vick, N., Grimm, S., Tremont-Lukats, I. W., De Groot, J., Aldape, K., Gilbert, M. R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826294/
https://ncbi.nlm.nih.gov/pubmed/26476729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1958-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !